Novo Nordisk A/S (NYSE:NVO) to Issue $0.58 Dividend

Novo Nordisk A/S (NYSE:NVO) announced a dividend on Wednesday, August 5th. Shareholders of record on Monday, August 17th will be paid a dividend of 0.5786 per share on Tuesday, August 25th. This represents a yield of 254.0%. The ex-dividend date is Monday, August 17th.

Novo Nordisk A/S has increased its dividend payment by an average of 0.2%per year over the last three years. Novo Nordisk A/S has a dividend payout ratio of 36.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Novo Nordisk A/S to earn $3.28 per share next year, which means the company should continue to be able to cover its $1.74 annual dividend with an expected future payout ratio of 53.0%.

Novo Nordisk A/S Stock Up 2.9%

Shares of NVO stock traded up $1.27 during mid-day trading on Thursday, hitting $45.80. The stock had a trading volume of 7,925,164 shares, compared to its average volume of 18,239,865. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm’s 50-day moving average is $46.96 and its two-hundred day moving average is $45.12. The firm has a market capitalization of $204.50 billion, a P/E ratio of 11.20, a price-to-earnings-growth ratio of 4.03 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion for the quarter. On average, analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVO has been the topic of a number of research reports. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. BMO Capital Markets reissued a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Five research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $65.81.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.